Latest International Markets News

RooLife Group (ASX: RLG) reported a 268% jump in FY2026 revenue to nearly $10 million, driven by rapid growth in its own food and beverage products, including RLG Coffee in China. Despite this, the company recorded a $3.58 million net loss, weighed down by impairment charges and R&D investments in renewable energy.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

Spacetalk Ltd reported a 17% revenue decline in FY26 amid a strategic reset, but mobile revenue grew 16% as the company pivots to a software-led family safety platform supported by new telco partnerships.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.

Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.

Advanced Braking Technology Ltd (ASX: ABV) posted a 22.7% revenue increase to $23.48 million and a 16.6% rise in net profit after tax to $2.075 million for FY26, driven by international expansion and advances in autonomous braking technology.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.